临床药师参与1例华法林个体化抗凝治疗的药学实践

doi:10.19803/j.1672-8629.2020.12.20

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (12): 939-942.
DOI: 10.19803/j.1672-8629.2020.12.20

临床药师参与1例华法林个体化抗凝治疗的药学实践

李宇¹, 樊晖晖¹, 冯晓俊², 王运红¹, 陈传涛¹, 张蕾^2*

¹太和县人民医院药剂科,安徽太和 236600;
²中国科学技术大学附属第一医院,安徽省立医院药剂科,安徽合肥 230001

收稿日期:2019-10-21 修回日期:2020-12-07 出版日期:2020-12-15 发布日期:2020-12-07
通讯作者: ^*张蕾,女,博士,副主任药师,药物基因组学。E-mail:76zhanglei@126.com
作者简介:李宇,男,硕士,药师,临床药学。
基金资助:
太和县科技项目(2018WS5009)

Individualized Anticoagulant Therapy for Warfarin in a Patient with Poor Metabolism

LI Yu¹, FAN Huihui¹, FENG Xiaojun², WANG Yunhong¹, CHEN Chuantao¹, ZHANG Lei^2*

¹Department of Pharmacy,People's Hospital of Taihe County,Taihe Anhui 236600,China;
²Department of Pharmacy,the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital),Hefei Anhui 230001,China

Received:2019-10-21 Revised:2020-12-07 Online:2020-12-15 Published:2020-12-07

摘要/Abstract

摘要： 目的探讨临床药师在华法林个体化抗凝治疗中的作用。方法临床药师参与1例患者的华法林个体化抗凝治疗过程,根据指南建议停用阿司匹林,单用华法林治疗。根据基因检测结果调整华法林剂量,并随访行凝血酶原时间、国际标准化比值及有无出血事件发生等药学监护。结果医生接受临床药师建议,停阿司匹林,应用华法林1.25 mg/d,检查结果均在目标范围内,无出血和栓塞事件发生。结论临床药师通过基因检测指导华法林个体化给药,保障患者用药安全和有效,实现抗凝治疗的全程化、个体化、最优化。

关键词: 细胞色素P4502C9和维生素K环氧化物还原酶复合体1基因, 华法林, 个体化, 抗凝, 药学实践

Abstract: Objective To investigate the role of clinical pharmacists in individualized anticoagulation therapy of warfarin.Methods The clinical pharmacist participated in the individualized anticoagulant treatment of warfarin in one patient. According to the guidelines, the clinical pharmacist recommend discontinuing aspirin and using warfarin monotherapy. The dose of warfarin was adjusted according to the genetic test results, the prothrombin time, INR and the occurrence of bleeding events and other pharmaceutical monitoring datas were followed.Results The doctor accepted the advice of clinical pharmacists, discontinued aspirin and warfarin 1.25mg/d was applied. The detection results were within the target range, no bleeding and embolic events occurred.Conclusion Clinical pharmacists guide individualized administration of warfarin through genetic testing to ensure the safety and effectiveness of medication for patients and realize the whole-process, individualization and optimization of anticoagulation therapy.

Key words: CYP2C9 and VKORC1 genes, warfarin, individualization, anticoagulation, pharmaceutical care

中图分类号:

R973R969.3

李宇, 樊晖晖, 冯晓俊, 王运红, 陈传涛, 张蕾. 临床药师参与1例华法林个体化抗凝治疗的药学实践[J]. 中国药物警戒, 2020, 17(12): 939-942.

LI Yu, FAN Huihui, FENG Xiaojun, WANG Yunhong, CHEN Chuantao, ZHANG Lei. Individualized Anticoagulant Therapy for Warfarin in a Patient with Poor Metabolism[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 939-942.

参考文献

[1] Go AS,Hylek EM,Phillips KA,et al.Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study[J].JAMA,2001,85(18):2370-2375.
[2] Yi X,Lin J,Han Z,et al.Preceding Antithrombotic Treatment Is Associated with Acute Ischemic Stroke Severity and Functional Outcome at 90 Days among Patients with Atrial Fibrillation[J].J Stroke Cerebrovasc Dis,2019,28(7):2003-2010.
[3] Chinese Society of Cardiology,Committee of Cardio-Cerebral-Vascular Diseases of Gerontological Society of China.Chinese Expert Consensus on Warfarin Anticoagulation Therapy[J].Chinese Journal of Internal Medicine(中华内科杂志),2013,52(1):76-82.
[4] Zhang S,Yang YM,Huang CX,et al.Guideline of stroke prevention in Chinese patients with atrial fibrillation(2017)[J].Chinese Journal of Cardiac Arrhythmias(中华心律失常学杂志),2018,22(1):17-30.
[5] Peng J,Tan SL,Zhou HH,et al.Pharmacogenomics of warfarin and its personalized treatment[J].Chinese Pharmacological Bulletin(中国药理学通报),2013,29(2):169-172.
[6] Wang TY.Effectively Initiating and Maintaining Anticoagulation in Patients with Atrial Fibrillation[J].Circulation,2019,139(15):1763-1765.
[7] Lévy S,Maarek M,Coumel P,et al.Characterization of different subsets of atrial fibrillation in general practice in France:the ALFA study.The College of French Cardiologists[J].Circulation,1999,99(23):3028-3035.
[8] Siu CW,Tse HF.Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation[J].Circ Arrhythm Electrophysiol,2014,7(2):300-306.
[9] Li Z,Zhang DF,Zou M,et al.The effect of whole-course pharmaceutical monitoring on anticoagulant therapy in patients with atrial fibrillation[J].Chinese Journal of Hospital Pharmacy(中国医院药学杂志),2019,39(6):628-631.
[10] Hou KL,Yang YH,Wang ZH,et al.Effectiveness of Pharmacist-Participated Warfarin Anticoagulation Management on Patients with Pulmonary Embolism[J].Chinese Pharmaceutical Journal(中国药学杂志),2018,53(8):646-651.
[11] Yin T,Miyata T.Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives[J].Thromb Res,2007,120(1):1-10.
[12] Lou Y,Liu H,Han LL,et al.Influence of CYP2C9 and VKORC1 Genetic Polymorphisms on Maintenance Warfarin Dose in Chinese Pulmonary Embolism Patients[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2012,9(4):202-204.
[13] Syn NL,Wong AL,Lee SC,et al.Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry:a randomized controlled trial[J].BMC Med,2018,16(1):104.
[14] Biswas M,Bendkhale SR,Deshpande SP,et al.Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin:Results of a 5 years audit[J].Indian Heart J,2018,70(Suppl 3):S13-S19.
[15] Hosseinkhani Z,Sadeghalvad M,Norooznezhad F,et al.The effect of CYP2C9*2,CYP2C9*3,and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah[J].Res Pharm Sci,2018,13(4):377-384.
[16] Wang KL,Lip GY,Lin SJ,et al.Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation:Meta-Analysis[J].Stroke,2015,46(9):2555-2561.
[17] Abraham NS,Singh S,Alexander GC,et al.Comparative risk of gastrointestinal bleeding with dabigatran,rivaroxaban,and warfarin:population based cohort study[J].BMJ,2015(350):h1857.

临床药师参与1例华法林个体化抗凝治疗的药学实践

Individualized Anticoagulant Therapy for Warfarin in a Patient with Poor Metabolism

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[2]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[3]	杨彩华, 杨龙娜, 李小波. 妊娠早期暴露低剂量华法林钠片后致胎儿畸形2例分析[J]. 中国药物警戒, 2023, 20(11): 1286-1289.
[4]	张雯雯, 聂西庭, 徐会茹, 冉晔, 田成林, 于生元. 华法林片联合复方氨酚烷胺片致凝血功能极度异常1例分析[J]. 中国药物警戒, 2023, 20(11): 1290-1292.
[5]	刘甜甜, 曹俊岭, 张彦丽, 巩颖, 顾媛媛. 活血化瘀中药增强华法林抗凝作用及机制的研究进展[J]. 中国药物警戒, 2023, 20(1): 117-120.
[6]	温都苏, 孙建军, 王毅. 药师参与华法林抗凝治疗对临床安全性和有效性的Meta分析[J]. 中国药物警戒, 2022, 19(9): 1009-1014.
[7]	朱金颖, 周素凤, 王璐, 许明哲, 邵凤. 基于药动/药效学建模与模拟的中枢镇静类儿科用药研究进展[J]. 中国药物警戒, 2022, 19(7): 721-727.
[8]	向云霞, 蒲文, 李东锋. 药师干预对心脏瓣膜置换术后华法林治疗患者抗凝治疗管理的影响[J]. 中国药物警戒, 2022, 19(5): 545-549.
[9]	柴晓利, 张臣, 丰庆春, 刘欢. 非瓣膜性心房颤动老年患者用药现状及影响因素分析[J]. 中国药物警戒, 2022, 19(3): 302-305.
[10]	郭军, 任丹, 叶龙, 赵荣香, 王宇, 余静. 华法林片致儿童非创伤性自发性肌肉出血1例分析[J]. 中国药物警戒, 2022, 19(3): 339-341.
[11]	张青霞, 丁倩, 闫素英, 王育琴. 达比加群酯和利伐沙班用药错误报告分析及防范策略[J]. 中国药物警戒, 2022, 19(12): 1372-1375.
[12]	吴婷, 吕小琴. 华法林致药物性肝损伤报告分析[J]. 中国药物警戒, 2021, 18(4): 365-367.
[13]	白荷荷, 聂晓静, 夏丽, 赵萌, 王金萍, 姚燕琴. 华法林相关肾病的1例病例报道及文献分析[J]. 中国药物警戒, 2020, 17(12): 934-938.
[14]	朱明静, 张丹丹, 杨滢, 杨悦. 口服抗凝药治疗非瓣膜心房颤动有效性和安全性贝叶斯网络Meta分析[J]. 中国药物警戒, 2020, 17(10): 726-731.
[15]	罗敏, 徐珽. 1例经导管主动脉瓣置入术治疗后患者合用华法林与抗菌药物的药学监护[J]. 中国药物警戒, 2017, 14(9): 555-558.